SMW Free Realtime Trade Alerts -- Fast Moving Stocks < $15 -- Join Today for FREE!!
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Loading IDRA News...
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | -0.35% | 78.97 | 1.1% | $778.95m | |
| SRPT | Sarepta Therapeutics, Inc. | 5.31% | 62.24 | 27.0% | $475.37m | |
| AMGN | Amgen Inc. | -1.12% | 169.71 | 1.2% | $462.12m | |
| BIIB | Biogen Inc. | -1.27% | 310.55 | 1.1% | $427.51m | |
| MDVN | Medivation, Inc. | 0.05% | 81.48 | 1.9% | $393.20m | |
| CELG | Celgene Corporation | -1.46% | 105.83 | 0.9% | $388.18m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.56% | 419.10 | 3.7% | $315.62m | |
| CPHD | Cepheid | 0.11% | 52.69 | 5.5% | $214.32m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.76% | 123.76 | 2.2% | $173.50m | |
| CLVS | Clovis Oncology, Inc. | -2.94% | 36.34 | 28.4% | $163.46m | |
| ILMN | Illumina, Inc. | 0.35% | 180.98 | 3.4% | $139.93m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -0.31% | 88.84 | 2.3% | $127.85m | |
| INCY | Incyte Corporation | 4.64% | 93.20 | 2.8% | $120.53m | |
| BMRN | BioMarin Pharmaceutical Inc. | -1.05% | 96.03 | 4.0% | $114.07m | |
| TSRO | TESARO, Inc. | -3.35% | 104.42 | 17.5% | $109.74m |
Company Profile
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. Idera's immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while its third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden in May 25, 1989 and is headquartered in Cambridge, MA.